Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neon Therapeutics, Inc.NTGN · Entity 149433 | Chief Business Officer | February 27, 2019 | March 01, 2019 |
| Vor Biopharma Inc.VOR · Entity 4763 | Director · PRESIDENT AND CEO | May 06, 2025 | May 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neon Therapeutics, Inc.
Report date February 27, 2019 · Filed March 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 279,525 |
Reported balance
After 2019-02-27 transaction · row 1
1 source rowRow 1 · 2019-02-27 · Grant · Acquired 20,000 · Balance 279,525 F1: Dr. Ang was awarded 20,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.13 · Expires 2029-02-26 | Direct | 40,000 |
Reported balance
After 2019-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-27 · Grant · Acquired 40,000 · Balance 40,000 F2: This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Dr. Ang was awarded 20,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019.
Vor Biopharma Inc.
Report date May 06, 2025 · Filed May 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 911,318 |
Reported balance
After 2025-05-06 transaction · row 1
1 source rowRow 1 · 2025-05-06 · Tax withholding · Disposed 2,361 · Balance 911,318 F1: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2025 Filed May 7, 2025 20:05 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,361 | $0.56 | $1,322.16 |
DisclosureSEC source: 0001415889-25-012229 · form4-05072025_080553.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 911,318 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:28 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,522 | $0.66 | $1,664.52 |
DisclosureSEC source: 0001415889-25-011803 · form4-05022025_080547.xml · nonDerivative · entry 2 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 913,679 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:28 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,751 | $0.66 | $1,815.66 |
DisclosureSEC source: 0001415889-25-011803 · form4-05022025_080547.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 916,201 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:36 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,787 | $1.50 | $4,180.50 |
DisclosureSEC source: 0001415889-25-003366 · form4-02072025_090218.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 918,952 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 825,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 17 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 825,000 Underlying: Common Stock · 825,000 shares Expires 2035-02-02 F12 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2025, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 470,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 16 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,000 Underlying: Common Stock · 470,000 shares Expires 2034-01-28 F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F11 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 470,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 15 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 470,000 shares Expires 2034-01-28 F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F11 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 257,500 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 14 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,500 Underlying: Common Stock · 257,500 shares Expires 2033-02-05 F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F10 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 257,500 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 13 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257,500 shares Expires 2033-02-05 F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F10 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 172,500 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 12 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,500 Underlying: Common Stock · 172,500 shares Expires 2032-08-31 F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F9 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 172,500 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 11 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 172,500 shares Expires 2032-08-31 F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F9 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 376,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 10 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,000 Underlying: Common Stock · 376,000 shares Expires 2032-01-31 F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F8 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2022, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 376,000 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 9 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 376,000 shares Expires 2032-01-31 F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F8 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2022, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 51,060 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 8 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,060 Underlying: Common Stock · 51,060 shares Expires 2031-02-04 F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F7 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 19, 2021, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 51,060 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 7 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,060 shares Expires 2031-02-04 F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F7 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 19, 2021, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 652,086 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 6 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 652,086 Underlying: Common Stock · 652,086 shares Expires 2030-08-20 F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 652,086 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 5 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 652,086 shares Expires 2030-08-20 F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 147,294 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 4 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,294 Underlying: Common Stock · 147,294 shares Expires 2030-03-09 F6 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 147,294 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · derivative · entry 3 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 147,294 shares Expires 2030-03-09 F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 6 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · shares: On February 4, 2021, the Reporting Person filed a Form 3 which inadvertently reported that this stock option was for 147,293 shares, when in fact it was for 147,294 shares. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantCommon Stock | 137,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · nonDerivative · entry 2 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 921,739 F2 · shares: Represents the number of shares underlying RSUs. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2025, subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 3,248 | $1.34 | $4,352.32 |
DisclosureSEC source: 0001415889-25-003179 · form4-02062025_020220.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,239 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs"). Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,361 | $0.86 | $2,030.46 |
DisclosureSEC source: 0001415889-24-026429 · form4-11082024_041104.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 787,487 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,751 | $0.80 | $2,200.80 |
DisclosureSEC source: 0001415889-24-026126 · form4-11052024_041109.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 789,848 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 20:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 12,657 | $0.83 | $10,505.31 |
DisclosureSEC source: 0001415889-24-022768 · form4-09042024_040914.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 792,599 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:30 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,361 | $0.87 | $2,054.07 |
DisclosureSEC source: 0001415889-24-020990 · form4-08082024_080840.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 805,256 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,751 | $0.94 | $2,585.94 |
DisclosureSEC source: 0001415889-24-020739 · form4-08052024_040812.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 807,617 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| May 06, 2024 Filed May 7, 2024 20:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,361 | $1.75 | $4,131.75 |
DisclosureSEC source: 0001415889-24-012457 · form4-05072024_040501.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 810,368 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,751 | $1.77 | $4,869.27 |
DisclosureSEC source: 0001415889-24-012155 · form4-05032024_040507.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 812,729 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 12,657 | $2.27 | $28,731.39 |
DisclosureSEC source: 0001415889-24-006592 · form4-03052024_040323.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 815,480 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 22:08 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,788 | $2.32 | $6,468.16 |
DisclosureSEC source: 0001415889-24-003038 · form4-02082024_100240.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,137 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 00:35 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 470,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001415889-24-002098 · form4-02012024_120236.xml · derivative · entry 2 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,000 Underlying: Common Stock · 470,000 shares Expires 2034-01-28 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 00:35 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002098 · form4-02012024_120236.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,925 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2024, subject to the Reporting Person's continued service as of each such date. Read SEC document |
| November 06, 2023 Filed Nov 8, 2023 21:13 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,361 | $1.82 | $4,297.02 |
DisclosureSEC source: 0001209191-23-054699 · doc4.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680,925 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:28 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 12,657 | $2.67 | $33,794.19 |
DisclosureSEC source: 0001209191-23-048384 · doc4.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 683,286 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:29 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,361 | $2.67 | $6,303.87 |
DisclosureSEC source: 0001209191-23-045177 · doc4.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,943 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs"). Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:19 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 2,361 | $4.14 | $9,774.54 |
DisclosureSEC source: 0001209191-23-028473 · doc4.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 698,304 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs"). Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 23:39 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 12,657 | $5.51 | $69,740.07 |
DisclosureSEC source: 0001209191-23-014923 · doc4.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,665 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs"). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:28 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 257,500 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001209191-23-007794 · doc4.xml · derivative · entry 2 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,500 Underlying: Common Stock · 257,500 shares Expires 2033-02-05 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:28 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantCommon Stock | 128,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007794 · doc4.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,322 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning February 6, 2023, subject to the Reporting Person's continued service as of each such date. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 20:18 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 172,500 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001209191-22-050071 · doc4.xml · derivative · entry 2 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,500 Underlying: Common Stock · 172,500 shares Expires 2032-09-12 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 20:18 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantCommon Stock | 172,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050071 · doc4.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,572 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in four equal installments on each of March 1, 2023, September 1, 2023, March 1, 2024 and September 1, 2024, in each case, subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:25 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 376,000 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001209191-22-006790 · doc4.xml · derivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,000 Underlying: Common Stock · 376,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: This option vests over four years in equal monthly installments beginning on February 1, 2022. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:10 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 51,060 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008878 · doc4.xml · derivative · entry 1 ANG ROBERT · CIK 0001741283 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,060 Underlying: Common Stock · 51,060 shares Expires 2031-02-04 F1 · derivative.exercise_date: 1/48th of the shares underlying the option vest in equal monthly installments commencing on February 19, 2021, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 18:18 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $6.13 | $0.00 |
DisclosureSEC source: 0001694187-19-000011 · wf-form4_155148228112386.xml · derivative · entry 2 ANG ROBERT · CIK 0001741283 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-26 F2 · derivative.exercise_date: This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 18:18 UTC | Neon Therapeutics, Inc. NTGN · Entity 149433 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001694187-19-000011 · wf-form4_155148228112386.xml · nonDerivative · entry 1 ANG ROBERT · CIK 0001741283 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,525 F1 · shares: Dr. Ang was awarded 20,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.